- Home
- GMAB vs ITCI Comparison
GMAB vs ITCI Comparison
Compare GMAB & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ITCI
- Stock Information
- Founded
- GMAB 1999
- ITCI 2002
- Country
- GMAB Denmark
- ITCI United States
- Employees
- GMAB N/A
- ITCI N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- GMAB Health Care
- ITCI Health Care
- Exchange
- GMAB Nasdaq
- ITCI Nasdaq
- Market Cap
- GMAB 15.0B
- ITCI 13.5B
- IPO Year
- GMAB N/A
- ITCI N/A
- Fundamental
- Price
- GMAB $21.80
- ITCI $126.50
- Analyst Decision
- GMAB Buy
- ITCI Buy
- Analyst Count
- GMAB 8
- ITCI 13
- Target Price
- GMAB $43.00
- ITCI $100.31
- AVG Volume (30 Days)
- GMAB 1.1M
- ITCI 4.4M
- Earning Date
- GMAB 02-12-2025
- ITCI 02-20-2025
- Dividend Yield
- GMAB N/A
- ITCI N/A
- EPS Growth
- GMAB 14.35
- ITCI N/A
- EPS
- GMAB 10.80
- ITCI N/A
- Revenue
- GMAB $2,967,926,227.00
- ITCI $613,728,000.00
- Revenue This Year
- GMAB $32.03
- ITCI $48.41
- Revenue Next Year
- GMAB $16.97
- ITCI $38.26
- P/E Ratio
- GMAB $19.02
- ITCI N/A
- Revenue Growth
- GMAB 17.75
- ITCI 46.08
- 52 Week Low
- GMAB $19.85
- ITCI $62.78
- 52 Week High
- GMAB $31.88
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- GMAB 54.72
- ITCI 85.99
- Support Level
- GMAB $19.89
- ITCI $126.16
- Resistance Level
- GMAB $21.26
- ITCI $128.00
- Average True Range (ATR)
- GMAB 0.42
- ITCI 2.23
- MACD
- GMAB 0.02
- ITCI 4.40
- Stochastic Oscillator
- GMAB 80.08
- ITCI 96.82
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.